Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have been given an average rating of “Moderate Buy” by the sixteen brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $146.00.

Several analysts have recently commented on the stock. Truist Financial lifted their target price on shares of Abivax from $135.00 to $155.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. Jefferies Financial Group raised shares of Abivax from a “hold” rating to a “buy” rating and increased their price target for the stock from $108.00 to $158.00 in a report on Tuesday, June 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. Wolfe Research set a $136.00 price objective on Abivax in a report on Wednesday, June 3rd. Finally, Barclays boosted their target price on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ABVX. UBS Group AG boosted its position in shares of Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after purchasing an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. acquired a new position in shares of Abivax during the 3rd quarter worth $263,698,000. Morgan Stanley grew its stake in shares of Abivax by 114.3% during the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock worth $425,062,000 after purchasing an additional 1,681,277 shares during the period. Paradigm Biocapital Advisors LP purchased a new position in shares of Abivax in the 3rd quarter valued at about $132,800,000. Finally, TCG Crossover Management LLC lifted its stake in shares of Abivax by 17.4% in the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after purchasing an additional 1,055,000 shares during the period. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Price Performance

Abivax stock opened at $142.17 on Wednesday. The business has a 50 day simple moving average of $113.80 and a 200-day simple moving average of $118.19. Abivax has a 12 month low of $7.70 and a 12 month high of $148.83. The stock has a market capitalization of $11.34 billion, a PE ratio of -27.29 and a beta of 0.87.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $0.40 million. As a group, equities research analysts anticipate that Abivax will post -3.26 EPS for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.